A Single Center, Open Label, Dose-Finding Study to Determine the Safety of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation.
Phase of Trial: Phase I/II
Latest Information Update: 03 Jun 2014
At a glance
- Drugs Icotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Zhejiang Beta Pharma
- 13 Feb 2014 As per the ClinicalTrials.gov record, status changed from recruiting to completed.
- 27 Dec 2013 Planned End Date changed from 1 Sep 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 05 Jun 2013 Planned End Date changed from 1 Aug 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.